Physician

William Curry Mcevoy, M.D.

According to 2025 Medicare claims, William Mcevoy, M.D. (NPI: 1821222761) practices hematology/oncology in the Daphne-Fairhope-Foley, AL market, with the plurality of this provider's patient population coming from Baldwin, AL. This provider's primary affiliated billing organization is SOUTHERN CANCER CENTER, PC (NPI: 1578629556; TIN: 208097639) and primary practice location at 36535-2229.

Mcevoy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 823 traditional Medicare patients, billed 265,438 HCPCS/CPT codes, and received $4,105,338 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,373 prescription claims across 400 beneficiaries totaling $6,743,166 in drug costs, led by Brukinsa (Zanubrutinib). 2023 DME data shows 13 claims. Open Payments data shows 152 records totaling $3,187. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $300,814 to $4,105,338. Similarly, Part D prescription costs have moved sharply higher in recent years, from $15,757 to $6,743,166. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	191	20,556	$300,814
2016	570	186,950	$1,661,826
2017	739	226,514	$2,569,427
2018	793	214,430	$2,947,189
2019	696	269,171	$3,854,832
2020	641	266,106	$3,932,068
2021	665	207,821	$3,754,033
2022	716	196,849	$4,162,145
2023	790	281,956	$4,663,073
2024	823	265,438	$4,105,338

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	48	73	$15,757
2016	217	980	$646,864
2017	274	1,430	$1,499,393
2018	311	1,695	$2,037,562
2019	349	1,735	$2,641,292
2020	371	1,949	$3,170,692
2021	397	2,134	$4,012,038
2022	402	2,201	$5,682,940
2023	366	2,324	$4,547,251
2024	400	2,373	$6,743,166

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	13	$245
2018	N/R	12	$217
2019	N/R	N/R	N/R
2020	N/R	25	$2,407
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	13	$245
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	358	1,088	$88
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	477	1,203	$12
80053	Blood test, comprehensive group of blood chemicals	492	1,347	$10
36415	Insertion of needle into vein for collection of blood sample	536	1,836	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	481	1,659	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	61	1,830	$879,756
Lenalidomide	Lenalidomide	56	1,568	$849,311
Pomalyst	Pomalidomide	35	980	$783,536
Xtandi	Enzalutamide	53	1,590	$656,929
Cabometyx	Cabozantinib S-Malate	14	596	$471,837

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	152	$3,187	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for William Curry Mcevoy, M.D.?

Tedicare shows public-source Medicare data for William Curry Mcevoy, M.D. (NPI 1821222761), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does William Curry Mcevoy, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to William Curry Mcevoy, M.D.?

William Curry Mcevoy, M.D. is linked to SOUTHERN CANCER CENTER, PC (billing NPI 1578629556) in the available physician profile data.

Does William Curry Mcevoy, M.D. have Open Payments data?

William Curry Mcevoy, M.D. has 152 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.